⌘K
Loading ticker…
As of 2026-08-24, Xilio Therapeutics, Inc. Common Stock (XLO) has a 3-month relative strength percentile of 69 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 50. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.2%, relative volume 0.14×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
XLO is held by 2 ETFs as of Mar 2026. Top owner: VXF at 0.00% weight, $495K notional.
Held by 2 ETFs · $930K across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $495K | — |
| VTIVanguard Total Stock Market ETF | 0.00% | $435K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | XLO Jan avg: 5.15% median: 5.55% win: 50% σ: 27.28% n: 4 2022-04-12 → 2026-07-31 | XLO Feb avg: 6.32% median: 3.99% win: 50% σ: 16.95% n: 4 2022-04-12 → 2026-07-31 | XLO Mar avg: 8.45% median: 0.76% win: 50% σ: 32.61% n: 4 2022-04-12 → 2026-07-31 | XLO Apr avg: -9.77% median: -3.70% win: 40% σ: 22.55% n: 5 2022-04-12 → 2026-07-31 | XLO May avg: 5.56% median: 3.85% win: 60% σ: 21.03% n: 5 2022-04-12 → 2026-07-31 | XLO Jun avg: -10.45% median: -12.27% win: 20% σ: 18.13% n: 5 2022-04-12 → 2026-07-31 | XLO Jul avg: -0.15% median: -0.69% win: 40% σ: 5.69% n: 5 2022-04-12 → 2026-07-31 | XLO Aug avg: -6.04% median: -4.66% win: 50% σ: 13.27% n: 4 2022-04-12 → 2026-07-31 (current) | XLO Sep avg: 3.90% median: 6.09% win: 50% σ: 25.93% n: 4 2022-04-12 → 2026-07-31 | XLO Oct avg: 9.99% median: -0.83% win: 50% σ: 35.48% n: 4 2022-04-12 → 2026-07-31 | XLO Nov avg: -18.64% median: -9.54% win: 25% σ: 27.79% n: 4 2022-04-12 → 2026-07-31 | XLO Dec avg: -13.91% median: -13.94% win: 25% σ: 20.47% n: 4 2022-04-12 → 2026-07-31 |